June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Topical netarsudil for the treatment of canine corneal endothelial degeneration
Author Affiliations & Notes
  • M Isabel Casanova
    Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, United States
  • Nayeli Echeverria
    Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, United States
  • Morgan AW Bowman
    Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, United States
  • Melaney Annette Mayes
    Veterinary Medical Teaching Hospital, University of California Davis School of Veterinary Medicine, Davis, California, United States
  • Kathryn L Good
    Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, United States
    Department of Ophthalmology & Vision Science, University of California Davis School of Medicine, Sacramento, California, United States
  • Brian C Leonard
    Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, United States
    Department of Ophthalmology & Vision Science, University of California Davis School of Medicine, Sacramento, California, United States
  • Christopher J Murphy
    Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, United States
    Department of Ophthalmology & Vision Science, University of California Davis School of Medicine, Sacramento, California, United States
  • Sara M Thomasy
    Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, United States
    Department of Ophthalmology & Vision Science, University of California Davis School of Medicine, Sacramento, California, United States
  • Footnotes
    Commercial Relationships   M Isabel Casanova Aerie Pharmaceuticals, Code F (Financial Support); Nayeli Echeverria Aerie Pharmaceuticals, Code F (Financial Support); Morgan Bowman Aerie Pharmaceuticals, Code F (Financial Support); Melaney Mayes Aerie Pharmaceuticals, Code F (Financial Support); Kathryn Good Aerie Pharmaceuticals, Code F (Financial Support); Brian Leonard Aerie Pharmaceuticals, Code F (Financial Support); Christopher Murphy Aerie Pharmaceuticals, Code F (Financial Support); Sara Thomasy Aerie Pharmaceuticals, Code F (Financial Support)
  • Footnotes
    Support  Supported by the AKC Canine Health Foundation, NIH R01EY016134, P30EY12576, and K08EY028199, the Jane Lin Fong Ophthalmic Clinical Trial Support Fund and matching funds from the Center for Companion Animal Health, School of Veterinary Medicine, University of California, Davis.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2748 – A0237. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M Isabel Casanova, Nayeli Echeverria, Morgan AW Bowman, Melaney Annette Mayes, Kathryn L Good, Brian C Leonard, Christopher J Murphy, Sara M Thomasy; Topical netarsudil for the treatment of canine corneal endothelial degeneration. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2748 – A0237.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We evaluated the tolerability and efficacy of the topical rho-kinase inhibitor netarsudil in the treatment of canine corneal endothelial degeneration (CED).

Methods : Eighteen eyes of 14 client-owned dogs with CED were enrolled in a prospective, randomized, placebo-controlled clinical trial. The patients received topical netarsudil 0.02% (Rhopressa©, Aerie Pharmaceuticals) or vehicle control twice daily for the initial 4 months, then all patients received netarsudil for the final four months. Ophthalmic examination with measurement of Schirmer tear test I (STT), intraocular pressure (IOP), anterior segment photography, ultrasonic pachymetry (USP), Fourier-domain optical coherence tomography (FD-OCT), and in-vivo confocal microscopy was performed prior to and at 1, 2, 4, 6 and 8 months throughout treatment. The effect of treatment on corneal thickness, corneal stromal thickness, percentage of cornea affected by edema, and endothelial cell density (ECD) was evaluated by repeated measures ANOVA.

Results : Seven dogs (9 eyes) received placebo during the first 4 months, while 7 dogs (9 eyes) received netarsudil for 8 months. During netarsudil treatment, conjunctival hyperemia (n = 13), reticulated intraepithelial bullae (n = 1), and corneal stromal hemorrhage (n = 1) were identified were identified at one or more timepoints; one patient with stromal hemorrhage required temporary cessation of netarsudil for 1 month. Five eyes treated with netarsudil had decreased tear production at one or more timepoints during the study and required immunomodulatory treatment. No significant differences in corneal thickness, corneal stromal thickness, ECD, and percentage of the cornea affected by edema were observed between treatment groups or over time (p>0.05).

Conclusions : Netarsudil is generally well-tolerated in dogs with endothelial degeneration but may result in dry eye thus tear production should be closely monitored. While improvement was not observed in canine CED patients treated with topical netarsudil, interim analysis suggests stable disease after 4 or 8 months of treatment. Enrollment of more patients is required to fully evaluate the efficacy of netarsudil for canine CED.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×